Senores Pharmaceuticals Limited IPO: Another company will enter the IPO market. Senores Pharmaceuticals Limited is the name of this company.
This IPO has a value of Rs 582 crore. This IPO has a price range of Rs 372 to Rs 391 for each share. This IPO is scheduled to open on 20 December and close on 24 December.
The Ahmedabad-based firm’s IPO is a combination of new shares worth Rs 500 crore and a sale of 21 lakh shares valued at Rs 82.11 crore.
The IPO Has 75000 Shares Reserved For Employees
Senores Pharmaceuticals reserved 75 percent for qualified institution bidders (QIB), while non-institutional shareholders (NIIs), will receive a 15 percent allocation.
Retail investors will receive 10 percent of the shares.
What Will Happen To The Money?
The proceeds of the IPO will go towards the establishment of a production facility in Atlanta for the manufacture of sterile injectables, and to cover the working capital needs of the company.
A part of the proceeds will also be used for general company operations.
How Many Shares Are In A Lot?
Investors are allowed to apply for as little as 38 equity shares per lot. Ahmedabad’s company, founded in December 2017, manufactures and develops pharmaceutical products for the US, Canadian, and UK-regulated markets.
The company has three dedicated research and production facilities in India, the US, and Canada.
Equirus Capital and Ambit are the book-running leading managers for the Senores Pharmaceuticals IPO.
Link Intime India will be the registrar. The share of the company will be listed both on BSE and NSE, with a listing day of December 30,
Quarterly Results Of The Company
Senores Pharma posted a profit of Rs 23.94 crore for the six months ending September 30, 2024. The company reported revenue of Rs 183.35 crore.
The company reported a profit of Rs 32.71 crore with revenue of Rs 217.34 crore for the fiscal year 2023-24.
Quick Fact
| Company name | Senores Pharmaceuticals |
|---|---|
| IPO value | ₹582 crore |
| IPO price range | ₹372 to ₹391 per share |
| IPO dates | Opens: 20 December; Closes: 24 December |
| New share value | ₹500 crore |
| Sale of shares value | ₹82.11 crore |
| Employee reservation | 75,000 shares |
| QIB allocation | 75% |
| NII allocation | 15% |
| Retail allocation | 10% |
| Lot size | 38 shares |
| Established | December 2017 |
| Production facilities | India, US, Canada |
| Markets served | US, Canada, UK |
| IPO proceeds usage | Facility in Atlanta, working capital, operations |
| Book-running managers | Equirus Capital, Ambit |
| Registrar | Link Intime India |
| Listing date | 30 December |
| 6-month profit (Sept 2024) | ₹23.94 crore |
| 6-month revenue (Sept 2024) | ₹183.35 crore |
| Fiscal 2023-24 profit | ₹32.71 crore |
| Fiscal 2023-24 revenue | ₹217.34 crore |
Disclaimer: The website and its content are for informational purposes only and should not be considered investment advice.
